|
Crestor NewsWinder & Haslam provides the latest articles on Crestor. All of the files are in PDF format and require Adobe Acrobat to view. |
|
| Crestor
Drug May Be Riskier Than Thought New research seems to challenge an FDA decision not to pull the cholesterol-lowering drug Crestor off the market, with data showing it causes more kidney and muscle problems than rival medications. The FDA in March contended Crestor's risks were no greater than its competitors, and it rejected consumer efforts to remove the drug, made by AstraZeneca PLC, from store shelves. Instead, the FDA ordered a warning on the label, saying Crestor could cause serious muscle problems and kidney damage, especially among Asians. |
|
AstraZeneca's
Crestor Doubles Side Effects AstraZeneca's cholesterol-lowering drug Crestor has more than double the side effects of rival statin drugs, including deaths, U.S. researchers reported on Monday. Adverse effects include muscle damage known as myopathy, including a severe form known as rhabdomyolysis; proteinuria or protein in the urine; nephropathy, a reduced ability of the kidneys to filter toxins from the blood; and kidney failure. |
|
FDA
Warns AstraZeneca on Crestor Marketing For the second time in four months, the Food and Drug Administraton's Division of Drug Marketing, Advertising, and Communications (DDMAC) has warned AstraZeneca on advertisements promoting its cholesterol drug Crestor—calling suggestions that the drug is better than Pfizer's Lipitor "misleading." A spokesperson for AstraZeneca said the letter, a copy of which was obtained by Forbes.com, only applies to one ad campaign in the context of one specific portion of data from one study. AstraZeneca continues to believe that based on other comparative data it will be able to claim that Crestor is better at lowering bad cholesterol than all other statins. |
|
Crestor
Debate Intensifies The Food and Drug Administration is raising questions about the cholesterol-lowring drug Crestor, the newest in a class of drugs known as statins. The consumer group Public Citizen has long been calling for Crestor's recall, citing a high risk for a serious muscle disorder called rhabdomyolysis. |
|
Group
Seeks Criminal Probe of AstraZeneca A U.S. consumer group on Tuesday called for a criminal probe to determine if AstraZeneca illegally delayed reporting potential side effects from its cholesterol drug Crestor. Public Citizen, which has been lobbying to have Crestor pulled from the market, argued cases of a potentially life-threatening muscle breakdown as well as kidney damage were serious enough to have been quickly reported to regulators. |
|
Group
Alleges Delayed Reports of Crestor Side Effects A drug company illegally delayed reporting side effects linked to its anti-cholesterol drug Crestor, a consumer advocate contended Tuesday in urging a Food and Drug Administration investigation. It's the latest attack on Crestor by the private group Public Citizen, which argues that Crestor is riskier than its competitors and should be banned. |
|
Group
Ties More Illnesses to Cholesterol Drug A consumer health group, citing mounting cases of severe illness tied to the cholesterol-lowering drug Crestor, has taken its call for a ban on the pill to the pages of a leading medical journal. "To allow AstraZeneca to continue desperately seeking a piece of the estimated $20 billion-a-year statin market hardly justifies governments allowing this ultimately doomed drug to stay on the market," Dr. Sidney Wolfe, director of Public Citizen's Health Research Group, writes in the June 26 issue of The Lancet. |
|
| For more information about the Crestor lawsuit, please complete our convenient online contact form. |
|
Contact Winder & Haslam |
|
| |